SCYNEXIS (NASDAQ:SCYX) Now Covered by Aegis

Research analysts at Aegis assumed coverage on shares of SCYNEXIS (NASDAQ:SCYX) in a report released on Wednesday, The Fly reports. The firm set a “buy” rating on the stock.

SCYX has been the subject of a number of other reports. Zacks Investment Research lowered shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Needham & Company LLC restated a “buy” rating and issued a $5.00 price objective on shares of SCYNEXIS in a research note on Sunday, May 12th. LADENBURG THALM/SH SH set a $6.00 price objective on SCYNEXIS and gave the stock a “buy” rating in a research note on Friday, May 24th. Maxim Group set a $4.00 price objective on SCYNEXIS and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, ValuEngine lowered SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Saturday, May 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $4.25.

Shares of SCYX opened at $1.09 on Wednesday. The stock has a market cap of $61.16 million, a price-to-earnings ratio of -2.22 and a beta of 2.34. The company has a debt-to-equity ratio of 1.91, a quick ratio of 8.64 and a current ratio of 8.64. The company’s fifty day moving average is $1.25. SCYNEXIS has a 1-year low of $0.35 and a 1-year high of $1.90.

SCYNEXIS (NASDAQ:SCYX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.09 million. SCYNEXIS had a negative net margin of 12,254.69% and a negative return on equity of 127.47%. Research analysts expect that SCYNEXIS will post -0.9 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Creative Planning increased its stake in shares of SCYNEXIS by 153.5% in the 1st quarter. Creative Planning now owns 127,176 shares of the company’s stock worth $192,000 after purchasing an additional 77,000 shares in the last quarter. Bailard Inc. purchased a new stake in SCYNEXIS in the 1st quarter worth $196,000. Two Sigma Investments LP purchased a new stake in SCYNEXIS in the 4th quarter worth $80,000. Finally, Deutsche Bank AG purchased a new stake in SCYNEXIS in the 4th quarter worth $121,000. Hedge funds and other institutional investors own 30.64% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.

Read More: What is meant by holder of record?

The Fly

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.